Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-versus-Host Disease
Year: 2025
Type: article
Abstract: Background: Steroid-refractory acute graft-versus-host disease remains a lethal complication of allogeneic transplantation,and mesenchymal stromal cells have been given for two decades on largely uncontrolled evidence.Objective: To examine why single-arm series and randomised trials report irreconcilable response rates.Methods: Narrative review of single-arm cohorts, randomised trials, mechanistic studies and regulatory decisions.Findings: Single-arm studies reported 71% overall response in 55 patients and 83% at day 28 in 69 patients, whereasrandomised trials found day-28 complete response of 45% versus 46% placebo (192 treated) and 35% versus 30% (244treated). Placebo arms fell inside the single-arm range.Conclusions: The evidence supports immunomodulatory activity conditional on inflammatory licensing, but not the efficacyimplied by uncontrolled response rates. Function-based potency assays are required.
Source: Annals of Stem Cell Research
Authors: Fontaine E, Riis A, Salminen S
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7210279840
